GRI Bio’s (GRI) “Buy” Rating Reaffirmed at HC Wainwright

GRI Bio (NASDAQ:GRI)‘s stock had its “buy” rating reiterated by equities research analysts at HC Wainwright in a report released on Monday,Benzinga reports. They currently have a $10.00 price objective on the stock.

GRI Bio Stock Performance

Shares of NASDAQ GRI opened at $1.33 on Monday. The firm’s 50 day moving average price is $6.00 and its 200 day moving average price is $9.97. The firm has a market cap of $698,250.00, a P/E ratio of -0.12 and a beta of -1.72. GRI Bio has a 1 year low of $1.10 and a 1 year high of $130.39.

Institutional Trading of GRI Bio

A hedge fund recently raised its stake in GRI Bio stock. Geode Capital Management LLC increased its stake in GRI Bio, Inc. (NASDAQ:GRI) by 543.0% during the 4th quarter, according to its most recent Form 13F filing with the SEC. The fund owned 76,182 shares of the company’s stock after acquiring an additional 64,335 shares during the period. Geode Capital Management LLC owned approximately 0.85% of GRI Bio worth $63,000 as of its most recent SEC filing. 33.95% of the stock is owned by institutional investors.

GRI Bio Company Profile

GRI Bio, Inc, a clinical-stage biopharmaceutical company, focuses on treating inflammatory, fibrotic, and autoimmune diseases in the United States. Its product pipeline comprises GRI-0621, which is in phase II clinical development for the treatment of idiopathic pulmonary fibrosis; GRI-0803 which is in phase I trial for the treatment of systematic lupus erythematosus; GRI-0124, which is in pre-clinical development for the treatment of primary sclerosing cholangitis; and GRI-0729 in pre-clinical development.